Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

46 results about "Haemoglobin A1c" patented technology

Hemoglobin A1c is a protein on the surface of red blood cells that sugar molecules stick to, usually for the life of the red blood cell (about three months). The higher the level of glucose in the blood, the higher the level of hemoglobin A1c is detectable on red blood cells.

Method for determination of hemoglobins

A method for determining hemoglobins is provided which is suitable for determination of stable hemoglobin A1c. A method for determining hemoglobins by cation exchange liquid chromatography wherein an eluent is used containing a chaotropic ion and further an inorganic acid, an organic acid and / or any salt thereof having a buffer capacity in the 4.0-6.8 pH range.
Owner:SEKISUI CHEM CO LTD

Panel of biomarkers for peripheral arterial disease

ActiveUS20080171396A1Increases clinical index of suspicionGreat scrutinyDisease diagnosisBiological testingHaemoglobin A1cD-Glucose
The invention provides biomarkers including β-2-microglobulin, Cystatin C, hsCRP and glucose as well as methods for using the biomarkers for diagnosing and / or assessing the risk of peripheral artery disease in a subject. In some embodiments, the subject being tested may be suffering from or at risk of other circulatory diseases, including coronary artery disease. Hemoglobin A1c or other proxies for measuring glucose levels may be substituted for or measured in addition to glucose in the context of the present invention.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1

Ratiometric Immunoassay Method and Blood Testing Device

The invention is to devices and methods for rapid determination of analytes in liquid samples. The devices and methods incorporate a sample dilution feature and multiple immunosensors for performing a ratiometric immunoassay on a first analyte and a second analyte, for example, hemoglobin and hemoglobin A1c or albumin and glycosylated albumin. The devices are preferably capable of being used in the point-of-care diagnostic field.
Owner:ABBOTT POINT CARE

Hemoglobin A1c Determination Method, Enzyme to be Used therefor, and Production Method Thereof

There is provided a method for specifically determining a glycated β-chain N-terminal of glycated hemoglobin using enzymes without a separation operation, and a determination reagent kit therefor.A protease that cleaves a glycated amino acid and / or a glycated peptide from a glycated β-chain N-terminal without substantially cleaving a glycated amino acid or a glycated peptide from a glycated α-chain N-terminal of glycated hemoglobin or a fragment thereof is screened. The method of specifically determining a glycated β-chain N-terminal of glycated hemoglobin and the determination reagent kit are provided by using the protease obtained by the screening method.According to the present invention, a glycated β-chain N-terminal of glycated hemoglobin can specifically be determined without a separation operation.
Owner:ASAHI KASEI PHARMA

Handheld Dedicated Device for Diabetes Management

InactiveUS20070012324A1Reduce riskEasily and accurately track whatSurgeryDiagnostic recording/measuringCholesterolHand held
Handheld dedicated device for diabetes management. The device has nutritional information for 35,000 food items. Food items from fast food restaurants and various brands of food. The device provides a way of looking up all this information. The device can store information entered by the user of the device on food eaten, glucose levels, medication, insulin and exercise data. It also provides a way to save information from blood tests like Hemoglobin A1c which is an average of blood glucose levels over three months, blood pressure, and cholesterol. The input source for the device is keypad or voice command means.
Owner:NIRKONDAR RATNA +1

Diagnostic assay

For blood or other physiological fluid sample collection kits that use filter paper to collect the sample the performance of the kit and associated analytical method can be improved by using a material having properties which are superior to those of standard filter paper or modified filter paper routinely used in standard biological assays. Certain materials currently available for uses other than blood collection, storage, or transport have properties that are advantageous as employed in assays of biological fluids, including the use of specific glass fiber blotting materials for collecting blood samples for hemoglobin or hemoglobin A1c monitoring.
Owner:FLEXSITE RES & DEV

Hemolysis reagent composition for hemoglobin a1c quantitative analysis using enzymatic method

Disclosed is a hemolysis reagent composition for the quantitative analysis of glycated hemoglobin (HbAlc) via an enzymatic method. The hemolysis reagent compositions of the present invention containing a zwitterionic surfactant and a nitrous compound considerably accelerate hemolysis rate due to the presence of the zwitterionic surfactant, and also induce the N-terminal β-chain of hemoglobin released by hemolysis to be exposed to the outside of the hemoglobin molecule and assists the participation of a greater number of molecules in the reaction, thereby improving reaction sensitivity and reaction rate of the glycated hemoglobin, and the nitrous compound makes the protein structure of the hemoglobin flexibly modified so that the amino acid sequence of the N-terminal β-chain of hemoglobin can be readily cut off, thereby significantly reducing the entire time required for the measurement and improving the accuracy of the measurement.
Owner:I SENS INC

Hemoglobin determination method

An object of the present invention is to provide a method for measuring hemoglobin using electrophoresis, in particular a method for measuring hemoglobin that enables high accuracy measurement of stable hemoglobin A1c and a method for simultaneously measuring stable hemoglobin A1c and abnormal hemoglobins.The present invention provides a method for measuring hemoglobin using electrophoresis, which comprises: immobilizing an ionic polymer on an inner surface of a migration path; and using a buffer solution containing a sulfated polysaccharide.
Owner:SEKISUI CHEM CO LTD

Method for immunologically assaying hemoglobin a1c in specimen

Means that enables an immunoassay of hemoglobin A1c in a whole blood sample without pretreatment of the sample is disclosed. The immunoassay of hemoglobin A1c in a sample according to the present invention comprises bringing latex particles into contact with a non-pretreated whole blood sample in a hypotonic solution, and then bringing hemoglobin A1c adsorbed on the latex particles into contact with an anti-hemoglobin A1c antibody. The immunoassay is preferably carried out by an agglutination method. The hypotonic solution is, for example, a buffer containing a Good's buffer at a concentration of 0.02 to 0.2 mol / L, which Good's buffer has the maximum buffer capacity in the neutral to alkaline region.
Owner:FUJIREBIO CO LTD

Diagnostic assay

For blood or other physiological fluid sample collection kits that use filter paper to collect the sample, the performance of the kit and associated analytical method can be improved by using a material having properties which are superior to those of standard filter paper or modified filter paper routinely used in standard biological assays. Certain materials currently available for uses other than blood collection, storage, or transport have properties that are advantageous as employed in assays of biological fluids, including the use of specific cellulose blotting materials for collecting blood samples for hemoglobin or hemoglobin A1c monitoring.
Owner:FLEXSITE RES & DEV

Measuring device and measuring method

Provided is a device and a method, said device enabling the measurement of both of blood glucose level and hemoglobin A1c level, being small-sized and thus portable, allowing the measurement of a small amount of a specimen and, therefore, being usable in POC. The device for measuring the blood glucose level and hemoglobin A1c level of a blood specimen comprises: a test piece-mounting section (1) for detachably mounting test pieces (200) on which the blood specimen is to be spotted; a light-emitting section (2) for emitting light for irradiating the test pieces (200); a light-receiving section (3) for receiving reflected lights from the test pieces (200); and an operating section (4) for calculating the blood glucose level and hemoglobin A1c level of the blood specimen on the basis of photometric values obtained from the light-receiving section (3). As a test piece (200) for measuring the blood glucose level of the blood specimen, a test piece (A), which carries a composition (a) reacting with glucose and showing color development, is mounted. As a test piece (200) for measuring the hemoglobin A1c level of the blood specimen, a test piece (B), which carries a composition (b) reacting with glycated hemoglobin and showing color development, is mounted.
Owner:TOYOBO CO LTD

HEMOGLOBIN A1c-SPECIFIC APTAMER, HEMOGLOBIN-SPECIFIC APTAMER, AND APPLICATIONS THEREOF

The present invention provides a Hemoglobin A1c-specific aptamer and a Hemoglobin-specific aptamer. The aptamers were selected in vitro using SELEX and a microfluidic chip system. The aptamers established low free energy, thus were more stable than conventional antibodies. The high specificity of the aptamers to Hemoglobin A1c or Hemoglobin allows them to be effectively used in diagnosis of diabetes and / or anemia.
Owner:NATIONAL TSING HUA UNIVERSITY

Drug for improving hyperglycemia

A compound having a hyperglycemia improving effect and a hemoglobin A1c lowering action such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol is used as an active ingredient of a drug or food or drink for improving hyperglycemia.
Owner:MORINAGA MILK IND CO LTD

Saturation binding ratiometric assay

Methods, devices, and reagents are described for performing ratiometric assays for hemoglobin A1c. The methods involve a direct ratio determination between Hb A1c and normalized total hemoglobin utilizing a saturating amount of hemoglobin so that Hb A1c binds proportionately to a substrate. In some applications, the assay utilizes LOCI or other proximity label for signal generation and / or labeled magnetic beads. The methods can be configured as homogeneous or heterogeneous assays.
Owner:MANNEH VICTOR +1

CALIBRATION METHOD IN MEASUREMENT OF HEMOGLOBIN A1c

A calibration method that enables calibration easily in a short time in a measurement of hemoglobin A1c by use of a separation analysis is provided. In a measurement of a hemoglobin A1c amount by use of a separation analysis, a one-point calibration using a single calibration standard is performed to obtain calibration data to be used for correcting a measured value.
Owner:ARKRAY INC

Panel of biomarkers for peripheral arterial disease

InactiveUS7998743B2Increases clinical index of suspicionGreat scrutinyDisease diagnosisBiological testingCoronary artery diseaseBeta-2-Microglobulin Protein
The invention provides biomarkers including β-2-microglobulin, Cystatin C, hsCRP and glucose as well as methods for using the biomarkers for diagnosing and / or assessing the risk of peripheral artery disease in a subject. In some embodiments, the subject being tested may be suffering from or at risk of other circulatory diseases, including coronary artery disease. Hemoglobin A1c or other proxies for measuring glucose levels may be substituted for or measured in addition to glucose in the context of the present invention.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1

METHOD FOR MEASURING HbA1c

Provided is a method of avoiding the influence of a coexisting substance in the measurement of HbA1c % for a whole blood sample by an enzymatic method. Specifically, provided is a method of measuring a ratio of a hemoglobin A1c concentration to a hemoglobin concentration in a sample by an enzymatic method, the method including: a first step of optically measuring the hemoglobin concentration; and a second step of optically measuring the hemoglobin A1c concentration, wherein, when HbA1c % is calculated by dividing the hemoglobin A1c concentration measured in the second step by the hemoglobin concentration measured in the first step, the hemoglobin concentration serving as a denominator, which is measured at a first wavelength, is corrected using a result measured at a second wavelength.
Owner:SEKISUI MEDICAL CO LTD

Hypoglycemic preparation used for human body and its preparation method

The invention provides a hypoglycemic preparation for the human body. The hypoglycemic preparation includes at least one kind of probiotics, and the amount of each kind of probiotics is 107-1013 CFU, and the total amount of the probiotics in each hypoglycemic preparation is 8*107-8*1013 CFU. The invention further discloses a preparation method of a hypoglycemic preparation used for the human body. According to the hypoglycemic preparation used for the human body and its preparation method, the gastrointestinal function can be promoted, the body's immune system is regulated so as to correct the intestinal microbial disturbance, and the preparation has the effects of reducing hemoglobin A1c and treating the diabetes.
Owner:陈元秀

METHOD FOR MEASURING STABLE HEMOGLOBIN A1c USING LIQUID CHROMATOGRAPHY, AND METHOD FOR SIMULTANEOUS MEASUREMENT OF STABLE HEMOGLOBIN A1c AND ABNORMAL HEMOGLOBIN USING LIQUID CHROMATOGRAPHY

An object of the present invention is to provide a method capable of measuring stable hemoglobin A1c using liquid chromatography in a short time with good reproducibility.The present invention is a method for measuring stable hemoglobin A1c using liquid chromatography, installing on a flow path of a liquid chromatograph a filter whose surface is treated with a solution containing 1 to 50% by weight of a silicone oil or a solution containing 1 to 50% by weight of a silicone resin, and setting a pressure value generated in a measurement system of the liquid chromatograph to 9.8×103 Pa or more and 19.6×105 Pa or less.
Owner:SEKISUI MEDICAL CO LTD

Cellular hemoglobin a1c quality controls

Intact erythrocytes with selected and often elevated levels of hemoglobin A1c (HbA1c) for use as quality controls for HbA1c assays and assay instruments are prepared by hypotonic dialysis of erythrocytes from a healthy mammal to permeabilize the erythrocyte membranes, infusion of the permeabilized erythrocytes with hemoglobin A1c, and de-permeabilization of the infused erythrocytes. Quality controls of essentially any level of HbA1c can be prepared in this manner and once prepared will be useful for monitoring the entire assay procedure, including the lysis of the erythrocytes in a typical sample.
Owner:BIO RAD LAB INC

HbA1c measurement result display method, display device, and display program

InactiveCN102539594AInhibition of measurement resultsComponent separationHealth-index calculationDisplay deviceNormal values
The invention provides an HbA1c measurement result display method, display device, and display program. The method for displaying HbA1c measurement results is provided, which makes it possible to prevent overlooking a sample that exhibits an HbAlc value at a predetermined level different from a normal value, for example, a sample that exhibits a diabetic type. The method is a display method for displaying spectrum data as results of measurement of hemoglobin A1c (HbAlc) in a sample by separation analysis, and the method includes applying one of at least two different types of designs to a peak area for HbAlc in the spectrum data, according to an amount of HbAlc in the sample, or according to the amount of HbAlc and an amount of blood glucose in the sample.
Owner:ARKRAY INC

Method for determining alzheimer's disease risk

InactiveUS20190265256A1Determined accurately and easily and rapidly and cheaplyEasily and rapidly and cheaplyCompound screeningApoptosis detectionDisease riskGlycoalbumin
With the present invention, glycoalbumin and hemoglobin A1c are measured in a blood sample, and the incidence of or the existence or non-existence of a development risk of Alzheimer's disease can then be determined based on the calculated glycoalbumin / hemoglobin A1c ratio. Compounds for treating or preventing Alzheimer's disease can also be selected using this glycoalbumin / hemoglobin A1c ratio.
Owner:KYUSHU UNIV +1

Methods and compositions for treating diabetes with iPS derived pancreatic beta-like cells

Diabetes mellitus is characterized by either the inability to produce insulin (Type 1 diabetes) and or as insensitivity to insulin secreted by the body (Type 2 diabetes). In either case, the body is unable to efficiently move blood glucose across cell membranes to be utilized. This leads to a variety of local and systemic detrimental effects. Current treatments for diabetes focus on exogenous insulin administration and dietary control. Provided herein are treatments of diabetes using a cellular therapy to ameliorate symptoms associated with both reduced insulin secretion and insulin sensitivity. Using induced-pluripotent stem (iPS) cells, beta-like (ss-like) cells similar to the endogenous insulin secreting cells were derived.; These ss-like cells secreted insulin in response to glucose, and corrected a hyperglycemic phenotype in a mouse model of Type 2 diabetes via an iPS cell transplant. Within the Type 2 diabetes mouse model, a long term correction of hyperglycemia was achieved as measured by blood glucose and hemoglobin AIc measurements. Reduction of hyperglycemia was also seen in a chemically-induced mouse model for Type 1 diabetes.
Owner:Y 马 +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products